Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer

Breast Cancer Research

Volumn 11, Issue 4, 2009, Pages

  Trujillo, Miguel A ^a   Oneal, Michael J ^a   Davydova, Julia ^b   Bergert, Elizabeth ^a   Yamamoto, Masato ^b   Morris III, John C ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; E1A ASSOCIATED P300 PROTEIN; SODIUM IODIDE SYMPORTER; CAR RECEPTOR; COTRANSPORTER; E1A PROTEIN; HYBRID PROTEIN; MUC1 PROTEIN, HUMAN; MUCIN 1; RADIOACTIVE IODINE; SYNTHETIC DNA; VIRUS RECEPTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CYTOPATHOGENIC EFFECT; DEFECTIVE VIRUS; DRUG SCREENING; FEMALE; GENE VECTOR; GENETICS; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOPATHOGENIC EFFECT, VIRAL; DEFECTIVE VIRUSES; FEMALE; GENES, SYNTHETIC; GENETIC VECTORS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; MUCIN-1; PROMOTER REGIONS, GENETIC; RECEPTORS, VIRUS; RECOMBINANT FUSION PROTEINS; SYMPORTERS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73649119083     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2342     Document Type: Article

References (40)

1. American Cancer Society 2009, American Cancer Society., http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_people_get_breast_cancer_5.asp?sitearea=
2. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9:617-632. 10.1634/theoncologist.9-6-617, 15561806.
3. Carrasco N. Iodide transport in the thyroid gland. Biochim Biophys Acta 1993, 1154:65-82.
4. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR, Fischer AH, Mazzaferri EL. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998, 139:4416-4419. 10.1210/en.139.10.4416, 9751526.
5. Mazzaferri EL, Kloos RT. Carcinoma of follicular epithelium: radioiodine and other treatments and outcomes. The Thyroid: A Fundamental and Clinical Text 1996, 922-945. Philadelphia: Lippincott Raven, Braverman LE, Utiger RD, 7.
6. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 2007, 36:807-822. 10.1016/j.ecl.2007.04.006, 17673129.
7. Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Goke B, Morris JC, Spitzweg C. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005, 12:272-280. 10.1038/sj.gt.3302410, 15510175.
8. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005, 11:1483-1489. 10.1158/1078-0432.CCR-04-1636, 15746050.
9. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morrris JC. Sodium Iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006, 13:60-66. 10.1038/sj.gt.3302599, 16121204.
10. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001, 8:1524-1531. 10.1038/sj.gt.3301558, 11704812.
11. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, Blanco MC, Frisk CS, Marler RJ, Davis BJ, O'Connor MK, Russell SJ, Morris JC. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther 2005, 12:835-841. 10.1016/j.ymthe.2005.05.013, 16054438.
12. Gene therapy and radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy. , http://clinicaltrials.gov/ct/show/NCT00788307
13. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001, 6:339-353. 10.1023/A:1011379725811, 11547902.
14. Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor-Papadimitriou J. Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 1993, 268:9917-9926.
15. Chen L, Chen D, Manome Y, Dong Y, Fine HA, Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995, 96:2775-2782. 10.1172/JCI118347, 185987, 8675647.
16. Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 2007, 25:1607-1618. 10.1016/j.vaccine.2006.11.007, 1810513, 17166639.
17. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000, 106:763-771. 10.1172/JCI9180, 381391, 10995787.
18. Herrmann F. Cancer gene therapy: principles, problems, and perspectives. J Mol Med 1995, 73:157-163.
19. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007, 8:573-587. 10.1038/nrg2141, 17607305.
20. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002, 9:961-966. 12522435, 12522435, 10.1038/sj.cgt.7700535.
21. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376. 10.1126/science.274.5286.373, 8832876.
22. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993, 32:597-603. 10.1097/00006123-199304000-00016, 8386343.
23. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000, 7:1034-1038. 10.1038/sj.gt.3301197, 10871752.
24. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95:2509-2514. 10.1073/pnas.95.5.2509, 19394, 9482916.
25. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001, 3:385-394. 10.1006/mthe.2001.0275, 11273781.
26. Rasband WS. ImageJ. 1997, United States National Institutes of Health, Bethesda, Maryland, USA., http://rsbweb.nih.gov/ij/
27. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003, 63:7840-7844.
28. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984, 114:1090-1098. 10.1210/endo-114-4-1090, 6705729.
29. Boulanger PA. Adenovirus assembly: self-assembly of partially digested hexons. J Virol 1975, 16:1678-1682. 355776, 1202251.
30. Castro MR, Bergert ER, Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999, 84:2957-2962. 10.1210/jc.84.8.2957, 10443704.
31. Spitzweg C, Dutton CM, Castro MR, Bergert ER, Goellner JR, Heufelder AE, Morris JC. Expression of the sodium iodide symporter in human kidney. Kidney Int 2001, 59:1013-1023. 10.1046/j.1523-1755.2001.0590031013.x, 11231356.
32. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003, 63:5544-5550.
33. Humphreys MJ, Greenhalf W, Neoptolemos JP, Ghaneh P. The potential for gene therapy in pancreatic cancer. Int J Pancreatol 1999, 26:5-21. 10.1385/IJGC:26:1:5, 10566154.
34. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. Adv Exp Med Biol 2000, 465:171-180. full_text, 10810625.
35. Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Fukuhara M, Yanagi K, Matsushita A, Uchida E, Asaka M, Yoshida T, Aoki K. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett 2005, 218:53-62. 10.1016/j.canlet.2004.08.015, 15639340.
36. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006, 208:299-318. 10.1002/path.1896, 16362990.
37. Schmidt-Wolf G, Schmidt-Wolf IG. Human cancer and gene therapy. Ann Hematol 1994, 69:273-279. 10.1007/BF01696555, 7993934.
38. Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Hallden G, Mautner V, Shen Y, Seymour LW. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 2008, 19:873-886. 10.1089/hum.2008.047, 18710328.
39. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. The Na+/I- symporter of the thyroid gland. Soc Gen Physiol Ser 1993, 48:251-262.
40. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004, 10:5299-5312. 10.1158/1078-0432.CCR-0349-03, 15328165.